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High Prevalence of Low-Level Parasitemia With
Plasmodium vivax in Makira-Ulawa Province Presents a
Challenge for the Diagnosis and Eradication of Malaria in
Solomon Islands
James Fink, MBBS, MPH, FACP, FRACP, Peter D. Jones, MBBS, PhD, DCH, FRACP, GAICD
Department of Health Sciences and Medicine, Bond University, Robina, Gold Coast, Queensland, Australia
Background: Malaria remains endemic in Solomon Islands, but data on malaria in the provinces of Solomon Islands are limited.
This study from Makira-Ulawa Province aimed to identify the most prevalent strain of malaria and assess if the available rapid
diagnostic test (RDT) was effective in Kirakira Hospital.
Methods: Forty-five patients who presented to Kirakira Hospital with symptoms of fever had a positive malaria parasite smear
during a 4-weekperiod in 2017. Theparasite count for each smearwas calculated. Simultaneous testing using theCareStartMalaria
HRP2/pLDH (Pf/pan) Combo RDT was conducted. The data for all malaria parasite smears performed in Makira-Ulawa Province in
2016 were collated for comparison.
Results:All 45 patients diagnosedwithmalaria in a 4-week period in 2017were positive for Plasmodiumvivax. Themedian parasite
load was 280 parasites perμL (range, 160 to 640 parasites perμL). None of the 45 CareStart RDTs performedwas positive. In 2016,
5,505 of 17,195 patients (32.0%) screened hadmalaria parasites detected on amalaria parasite smear. P vivaxwas detected in 5,212
(94.7%) and Plasmodium falciparum in 285 (5.2%) of patients with malaria.
Conclusion: P vivax is the predominant strain of malaria present in Makira-Ulawa Province. RDTs were not helpful in the diagnosis
of malaria at Kirakira Hospital. The parasite load detected in the 45 patients diagnosed with malaria in this study was low. A focus
on attempting to eradicate P vivax in the community through improved compliance with treatment protocols is suggested as a
possible way forward to best manage malaria in Makira-Ulawa Province.
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INTRODUCTION
Malaria remains endemic in Solomon Islands, but progress
toward eradication has been slow and challenging. Despite
a reported reduction of 89% in confirmedmalaria cases from
1993 to 2011,1 wide discrepancies exist in the reported inci-
dences across the 9 provinces of Solomon Islands. In 2011,
rates ranged from 1.6 cases per 1,000 population in Isabel
Province to 96.8 cases per 1,000 population in Guadalcanal
Province.2
Since 2009, the diagnosis and treatment of malaria in
Solomon Islands has been available free of charge through
public health facilities. Artemisinin-based combination ther-
apy (ACT) has been the first-line treatment for all febrile
cases of acute malaria, with 14 days of primaquine used
for radical treatment of Plasmodium vivax. Glucose-6-
phosphate dehydrogenase (G6PD) screening has been a
requirement prior to commencing primaquine treatment.3
Limited data are available about malaria in Makira-
Ulawa Province of Solomon Islands. Makira-Ulawa is the
fifth largest province by population, estimated at 52,000
inhabitants in 2017, and is located approximately 180 km
southeast of Honiara, the capital city of Solomon Islands.4
Makira-Ulawa has one small hospital located in the provin-
cial capital Kirakira. Trained microscopists perform as many
as 50 malaria parasite smears each day at Kirakira Hospi-
tal. The hospital also has a store of rapid diagnostic test
(RDT) cartridges that have been shown to be accurate in
diagnosing acute malaria cases in other settings. However,
the nurses at Kirakira Hospital had stopped using the RDT
cartridges because they were “never positive” and “did not
work.” No specific data were available on when the nurses
stopped using the RDTs, but they had not been observed
using them since Bond University medical students started
completing placements in Kirakira Hospital in 2013.
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In response to these practical observations, we performed
a small prospective study of patients presenting to Kirakira
Hospital with fever and a positivemalaria parasite smear dur-
ing a 4-week period in 2017. Each of these patients also
underwent an RDT cartridge test. In addition, we reviewed
the laboratory results for all malaria parasite smears per-
formed during 2016 in Makira-Ulawa Province.
Information About Malaria
Malaria is a mosquito-borne infectious disease that,
according to the World Health Organization (WHO), is
responsible for more than 200 million episodes of illness
per year across the globe, resulting in up to 400,000 deaths
annually. Malaria is caused by the transmission of a para-
site from the female Anopheles mosquito into humans. The
disease has 4 known strains, but 2 strains—Plasmodium
falciparum and P vivax—are responsible for the majority of
clinical disease globally. Malaria disproportionately affects
the poorest countries of the world, with 85% of the total
disease burden borne by Africa and India.5 United Nations
Sustainable Development Goal 3.3 is to end the epidemics
of acquired immunodeficiency syndrome, tuberculosis, and
malaria by 2030.6,7 Attaining this goal for malaria is looking
increasingly out of reach for the Pacific countries.
P falciparum is the primary strain responsible for severe
malaria in Africa and India and accounts for more than 90%
of cases of malaria globally. P vivax is principally seen in
Southeast Asia, South America, and the Western Pacific.
Although the acute illness associated with P vivax malaria
is less severe than the illness associated with P falciparum,
P vivax has the potential to cause recurrent infection because
it can lie dormant in the liver. Chronic infection with P vivax
malaria can cause anemia and splenomegaly, can adversely
affect pregnancy, and is a significant cause of morbidity and
mortality in Solomon Islands.
Since 2001, the WHO has recommended the use of ACT
for acute treatment of malaria because of its efficacy against
both the P falciparum and P vivax strains.8 Since the intro-
duction of ACT, the number of malaria cases has been
reduced in the Southwestern Pacific. ACT was made the
first-line treatment for acute malaria in Solomon Islands in
2009, and during the next 6 years to 2015, the number of
malaria cases in Solomon Islands dropped by 75%.
From 2015 to 2020, however, the rate of decline in
the number of malaria cases slowed in Solomon Islands.
The 2019 malaria report from the WHO identifies P fal-
ciparum as responsible for more than 60% of malaria in
Solomon Islands.5 However, evidence suggests that P vivax
is now the overwhelming predominate strain of malaria in
the provinces.9 Actual data from the remote provinces of
Solomon Islands are very limited; the WHO figures are cal-
culated estimates. Research from Kirakira has shown that
these estimates can be very different from actual clinical data
taken from the medical records in Solomon Islands.10
METHODS
Ethics approval to conduct the research was granted by
the Human Research Ethics Committee of Bond University
(BURO 15397).
Patients presenting to the outpatient department of
Kirakira Hospital with a fever during April 2017 had a malaria
parasite smear taken and assessed by microscopists who
Table 1. Malaria Parasite Smear (MPS) Results for Febrile
















Note: One parasite per 200 white blood cells is calculated as being the
equivalent of 40 parasites per μL.
identified the strain of malaria and recorded the number of
parasites per 200 white blood cells. The number of parasites
per μL is estimated by assuming an average count of 8,000
white blood cells per μL, so 1 parasite per 200 white blood
cells is equivalent to 40 parasites per μL. A count of <1,000
parasites per μL is considered a low level of parasitemia in
acute malaria.
Consent was obtained from patients with a positive
malaria parasite smear to have an RDT performed on their
blood sample.11,12 RDTs were only performed on patients
with a positive malaria smear.
The available RDT at Kirakira Hospital was the CareStart
Malaria HRP2/pLDH (Pf/pan) Combo. The CareStart RDT
detects the histidine-rich protein 2 antigen of P falciparum
and Plasmodium lactate dehydrogenase that is produced by
all 4 species of malaria.13
The microscopists at Kirakira Hospital evaluate malaria
parasite smears for the entire province. Outside of Kirakira
Hospital, nurses at nurse-run health clinics assess patients
for fever and send malaria parasite smears to the hospital.
We audited all of the malaria parasite smears evaluated at
Kirakira Hospital in 2016. The only information available from
the audit was the strain of malaria. No information about the
parasite load could be retrieved.
RESULTS
In April 2017, 45 patients who presented with a fever to
Kirakira Hospital had a positive malaria parasite smear. All
patients were found to have P vivax. The median parasite
load was 7 per 200 white blood cells or 280 parasites per
μL. The highest parasite load detected was 16 per 200 white
blood cells or 640 parasites per μL (Table 1). In contrast,
none of the 45 CareStart RDTs performed was positive. No
patient had a clinically severe case of malaria. All patients
were managed as outpatients, and all patients recovered.
In 2016, 17,195 malaria parasite smears were evaluated
at Kirakira Hospital, resulting in 5,212 positives for P vivax,
285 positives for P falciparum, and 8 mixed species posi-
tives (Table 2). These results show that in 2016, 32.0% of
febrile patients seen in outpatient settings in Makira-Ulawa
Province had positive malaria parasite smears and that
P vivax was detected in 94.7% of cases, demonstrating that
P falciparum is an uncommon strain of malaria detected in
Makira-Ulawa Province.
DISCUSSION
Our study confirmed the suspicion of the local nursing staff
that the RDTs were not effective for diagnosing malaria in
Kirakira. This result is at odds with the reported sensitivi-
ties of RDTs that range between 75% and 90%. However,
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Table 2. Malaria Parasite Smear (MPS) Results From the
Kirakira Hospital Malaria Laboratory in 2016
Test/Results Adults Infants Total Percentage
MPS Performed 16,291 904 17,195 N/A
MPS Positive 5,284 221 5,505 32.0a
Plasmodium vivax 5,003 209 5,212 94.7b
Plasmodium falciparum 273 12 285 5.2b
Mixed species 8 0 8 0.1b
aPercentage of positive MPS tests overall (5,505/17,195).
bPercentage of positive MPS tests.
the studies of RDT sensitivities have principally been con-
ducted in the sub-Saharan region of Africa where P falci-
parum is the main species, the average parasite loads are
usually much greater than 1,000 parasites per μL, and lev-
els can be as high as 30,000 parasites per μL.14 The WHO
recommends the use of quality RDTs as standard diagnostic
tools for routine malaria case management, but evidence is
insufficient to assess if RDTs are useful in low-transmission
settings where submicroscopic infections, often not associ-
ated with febrile illness, have been shown to have efficient
gametocyte production that serves as an ongoing reser-
voir of potential transmission.15 Further research into the
sensitivity of the RDTs confirms that a parasite load of >500
parasites per μL is often required to trigger a positive result,
so RDTs are frequently unable to detect malaria in patients
with low parasite loads. In our study, 4 patients had para-
site loads >500 parasites per μL, but all had negative RDT
results.
The failure of the RDTs in this study could have several
explanations. The kits may have been defective, the staff
may not have used them correctly, and the low parasite loads
may have contributed to the ineffectiveness of the RDTs.
Because we only performed RDTs on patients with posi-
tive malaria parasite smears, we could not confirm a false-
positive rate for this particular RDT that has been noted by
Swiss researchers conducting fieldwork in Eswatini, formerly
known as Swaziland.16 RDTs are an important tool for the
detection of malaria in resource-poor communities without
access to microscopy; however, we had no success with the
RDT that was available. Kirakira Hospital had no access to
other RDTs that can distinguish between P falciparum and
P vivax strains and potentially might have been more effec-
tive than the CareStart Malaria HRP2/pLDH (Pf/pan) Combo
RDT.17 The total budget for all health care in Makira-Ulawa
Province is only $1.3 million US dollars per annum or the
equivalent of $26 US dollars per annum per capita, so health
care resources are extremely limited.18
Our study results demonstrate what appears to be a dra-
matic change in the epidemiology ofmalaria inMakira-Ulawa
Province. P falciparum in this audit was rare and accounted
for only 5.2% of identified cases vs the WHO estimate of
approximately 60%.5 A possible reason for this change is
the introduction of ACT protocols that are highly effective
against P falciparum and have been first-line treatment for all
cases of malaria in Solomon Islands since 2009. The staff in
the Kirakira Hospital malaria laboratory provided anecdotal
evidence that the clinics where P falciparum was detected
were remote and did not have access to ACT. The introduc-
tion of ACT in 2009 proved hugely successful in eradicating
P falciparum in Solomon Islands. In Makira-Ulawa Province,
however, the situation with P vivax is quite different.
P vivax malaria requires treatment with primaquine for 2
weeks to prevent recurrent infection. However, primaquine
can cause acute hemolytic anemia in patients with G6PD
deficiency. In Solomon Islands, research indicates that
approximately 7% of the population has a deficiency of
G6PD and would be at risk of developing a severe hemolytic
reaction when exposed to primaquine.19 Consequently,
since 2009, the Ministry of Health for Solomon Islands has
appropriately recommended that all patients with P vivax
malaria be screened for G6PD deficiency, and if safe, to pro-
ceed with primaquine treatment.20
Implementing this treatment protocol across Makira-
Ulawa Province has been challenging on many levels. First,
health literacy in the community is low, and the need for pri-
maquine treatment when the patient has recovered from the
acute febrile episode is often poorly understood by the nurs-
ing staff and the patients. Second, adherencewith outpatient
medication is a particularly challenging problem in Solomon
Islands. One strategy to overcome lack of adherence would
be to directly observe patients taking their primaquine med-
ication each day to ensure compliance, but resources to
implement such a policy are limited. Third, the G6PD screen-
ing test is not available at all health centers in Makira-Ulawa
Province, and the community and health workforce do not
have a clear understanding of why the test is important.21
An important issue raised by the study data is how the
diagnosis of acute malaria is made. The presence of a fever
and a positive malaria parasite smear have been considered
sufficient to establish a diagnosis of malaria. What we cannot
extract from this audit is whether the low-level parasitemia
was the cause of the fever or if patients had other common
causes of fever such as acute viral infection. The patients
diagnosed with malaria in this study were not sick enough
to require inpatient treatment and were effectively managed
on an outpatient basis. The highest parasite load among the
45 patients in this study was 640 parasites per μL (16 para-
sites per 200 white blood cells). This number is below the
level likely to cause symptoms of severe malaria (defined
as >1,000 parasites per μL or >25 parasites per 200 white
blood cells) and explains why all patients could be success-
fully managed as outpatients.
Whether the low-level parasitemia identified in this study
was sign of a chronic underlying illness and not the cause
of the fever is a vexing question because no agreed-upon
levels of parasitemia that indicate a definite diagnosis have
been established.22 Further, what constitutes symptomatic
vs asymptomatic malaria has not been firmly established.
Chronic or recurrent malaria has long been recognized to
cause long-term health problems such as chronic anemia
and splenomegaly.23
To answer the question of whether the low-level para-
sitemia identified in this study is a sign of a chronic under-
lying illness and not the cause of the fever would require
screening the population to determine the prevalence of
low-grade parasitemia, anemia, and clinical splenomegaly
in asymptomatic patients. Such population screening is not
part of the current national strategy to address malaria in
Solomon Islands.11 The number of cases of malaria detected
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in the province would have likely been higher if polymerase
chain reaction (PCR) had been used to screen for malaria
because this technology is more sensitive in identifying
malaria than microscopy or RDT.24 Asymptomatic malaria
is being recognized with increasing frequency in Southeast
Asia, with research using PCR technology revealing that 3 to
4 times as many patients with malaria may be detected with
PCR screening alone.
Developing an implementable combination of diagnos-
tic testing and treatment to try to eradicate malaria from
Makira-Ulawa Province will be an ongoing challenge.25
Malaria is a complex infection; the challenge is to under-
stand the nature of the illness and how that nature might
change as the epidemiology changes. Therefore, develop-
ing a better understanding of low parasite level and asymp-
tomatic disease is necessary for eradication programs to be
successful.
CONCLUSION
The epidemiology of malaria in Makira-Ulawa Province
has changed, with P vivax representing 94.7% of diag-
nosed cases and P falciparum having been almost eradi-
cated from the province. To meet the goal of Makira-Ulawa
being a malaria-free province by 2030, population screen-
ing is needed to determine the prevalence of low-level para-
sitemia in the province and if a significant burden of chronic
asymptomatic P vivax infection exists. Such a study should
be followed by a coordinated public health and implementa-
tion campaign that educates the public and health workforce
about the importance of adherence to treatment strategies
for the eradication of P vivax that include screening for G6PD
deficiency and a 14-day course of primaquine.
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